Cargando…

Correction: Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203388/ https://www.ncbi.nlm.nih.gov/pubmed/30365556 http://dx.doi.org/10.1371/journal.pone.0206719

Ejemplares similares

Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia
por: Oh, Esther S., et al.
Publicado: (2018)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Diagnostic Utility of CSF Tau and Aβ (42) in Dementia: A Meta-Analysis
por: Agarwal, Rachna, et al.
Publicado: (2011)

Ventricular volume in relation to lumbar CSF levels of amyloid-β 1–42, tau and phosphorylated tau in iNPH, is there a dilution effect?
por: Lidén, Simon, et al.
Publicado: (2022)

Correction: Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline
por: Asanad, Samuel, et al.
Publicado: (2020)

Levels of Cortisol in CSF Are Associated With SNAP-25 and Tau Pathology but Not Amyloid-β
por: Wang, Qing, et al.
Publicado: (2018)

Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β ((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop
por: Teunissen, Charlotte E., et al.
Publicado: (2010)

Correction to: BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease
por: Kim, Jun Pyo, et al.
Publicado: (2022)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Correction to: Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation
por: Shin, Woo Shik, et al.
Publicado: (2021)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

CSF tau and β-amyloid as biomarkers for mild cognitive impairment
por: Hampel, Harald, et al.
Publicado: (2004)

PICALM rs3851179 Variants Modulate Left Postcentral Cortex Thickness, CSF Amyloid β42, and Phosphorylated Tau in the Elderly
por: Wu, Zhiwei, et al.
Publicado: (2022)

Gray matter network properties show distinct associations with CSF p-tau 181 levels and amyloid status in individuals without dementia
por: Luigi, Lorenzini, et al.
Publicado: (2022)

Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds
por: Remnestål, Julia, et al.
Publicado: (2021)

Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review
por: Wilczyńska, Karolina, et al.
Publicado: (2020)

CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders
por: Mattsson, N, et al.
Publicado: (2013)

APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals – a cross-sectional observational study
por: Cysique, Lucette A, et al.
Publicado: (2015)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

Correction to: Protective effects of intracerebroventricular adiponectin against olfactory impairments in an amyloid β(1–42) rat model
por: Guzmán-Ruiz, Mara A., et al.
Publicado: (2021)

Correction: Protective effects of intracerebroventricular adiponectin against olfactory impairments in an amyloid β(1–42) rat model
por: Guzmán‑Ruiz, Mara A., et al.
Publicado: (2023)

Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia
por: Therriault, Joseph, et al.
Publicado: (2021)

CSF Potential Biomarkers Aβ42 and Tau: associations of Apo E Genotype
por: Kandimalla, Ramesh, et al.
Publicado: (2010)

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
por: Blennow, Kaj, et al.
Publicado: (2019)

Lower CSF Amyloid-Beta(1–42) Predicts a Higher Mortality Rate in Frontotemporal Dementia
por: Vieira, Daniela, et al.
Publicado: (2019)

Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Correction to: Caspase-1 variant influencing CSF tau and FDG PET levels in non-demented elders from the ADNI cohort
por: Liu, Yi, et al.
Publicado: (2022)

Tau and Amyloid-β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters
por: Schirinzi, Tommaso, et al.
Publicado: (2022)

Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
por: Wisch, Julie K., et al.
Publicado: (2023)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Correction to: Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
por: Thal, Dietmar Rudolf, et al.
Publicado: (2020)

Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

Cortical microstructural associations with CSF amyloid and pTau
por: Nir, Talia M., et al.
Publicado: (2023)

Correction: Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
por: Höglund, K., et al.
Publicado: (2018)

Correction to: Comprehensive characterization of elevated tau PET signal in the absence of amyloid-beta
Publicado: (2023)

Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
por: Lue, Lih-Fen, et al.
Publicado: (2017)

CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
por: Bibl, Mirko, et al.
Publicado: (2006)

Plasma p‐tau181/Aβ(1‐42) ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ(1‐42) and future cognitive decline
por: Fowler, Christopher J., et al.
Publicado: (2022)

Author Correction: The synergy of β amyloid 1-42 and oxidative stress in the development of Alzheimer’s disease-like neurodegeneration of hippocampal cells
por: Karapetyan, Gohar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e82fi4165692rk37gk0264gauh